Processa Pharmaceuticals

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Hanover, Maryland, focused on addressing unmet medical needs through the development of innovative drug products. The company's lead candidate, PCS499, is an oral tablet currently undergoing Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic skin condition. Additionally, Processa is advancing PCS12852, a selective 5-HT4 receptor agonist in Phase II trials aimed at treating post-operative ileus, and PCS6422, an irreversible inhibitor in Phase I trials targeting metastatic colorectal and breast cancer. The company also holds a licensing agreement with Akashi Therapeutics, Inc. for the development and commercialization of PCS100, an anti-fibrotic and anti-inflammatory drug. Founded in 2015, Processa Pharmaceuticals emphasizes a regulatory science approach to drug development, particularly in oncology, aiming to enhance the efficacy and safety of existing therapies.